Arca
Skip to content
Tools
Tools

GAA: Lysosomal alpha-glucosidase

Essential for the degradation of glycogen in lysosomes.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on GAA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Miglitol

Phase 30

    Phase 21

    • Duvoglustat

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      MiglitolApprovedPfizerSmall moleculeInhibitorLysosomal alpha-glucosidase inhibitor0
      DuvoglustatPhase 2Amicus TherapeuticsSmall moleculeStabiliserLysosomal alpha-glucosidase stabiliser0

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Glycogen storage disease II
      0.88
      Glycogen storage disease due to acid maltase deficiency, infantile onset
      0.68
      Glycogen storage disease due to acid maltase deficiency, late-onset
      0.64
      Disorder of glycogen metabolism
      0.63
      Type 2 diabetes mellitus
      0.58
      Abnormality of the cardiovascular system
      0.54
      Glycogen storage disease XV
      0.39
      Glycogen storage disease due to glycogen branching enzyme deficiency
      0.35
      Elevated circulating creatine kinase activity
      0.35
      Myopathy
      0.34
      Hereditary disease
      0.34

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      GAA

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2608, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P10253, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.